Your new post is loading...
Sanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicited a strong immune response against the Omicron variant. The French healthcare company said the “next-generation” booster jab delivered a “strong immune response” against variants of Covid, including Omicron, after two trials. It was safe and well tolerated in the study of 247 people. The vaccine makers said their jab increased antibodies to tackle the BA.1 Omicron strain by 40-fold in participants who had received two messengerRNA shots, the technology used in popular vaccines from Moderna and BioNTech/Pfizer. They reported that the vaccine outperformed a third dose of the current BioNTech/Pfizer jab, eliciting double the number of neutralising antibodies to BA.1 and BA.2. Thomas Triomphe, executive vice-president of Sanofi Vaccines, said Covid kept evolving and waning immunity was likely to lead to the need for additional booster shots, at least in some populations....
